The top 5 vaccine makers by 2013 revenue
July 24, 2014
Vaccines, which can be complicated and expensive to manufacture, haven't always been the moneymakers they are for some drugmakers today. Last year, the global vaccines market topped $25.56 billion according to EvaluatePharma, with the world's 6 top-selling shots each cracking the blockbuster barrier.
It's a small group of drugmakers that are enjoying vaccines' top-line success, and that club is only getting smaller as Novartis prepares to exit the space. Of course, all of that could change as the cancer immunotherapy vaccine field takes shape. A host of contenders, from small biotechs to Big Pharma companies, is working to bring a new crop of therapeutic cancer fighters to a market that could one day be worth billions.
Sign up for FierceVaccines's free email newsletter to see how those at the front of the pack are doing it and what lies ahead as they look to maintain their leads.
Current Subscribers: Please fill this form out once, and you won't see it again.
If you're having difficulty with this form, please email [email protected] for assistance.